Na Zhang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Na Zhang has a total of 25 co-authors. Here are the top co-authors by number of shared publications:
- Guofan Chen1 shared publication
- Hangzhou Luo1 shared publication
- Huaiming Peng1 shared publication
Jing Wu
Department of Basic Medicine of Medical School, Department of Infectious Diseases of Affiliated Hospital, Institute of Liver and Metabolic Diseases, Key Laboratory of Aging and Cancer Biology of Zhejiang Province, and Key Laboratory of Inflammation and Immunoregulation of Hangzhou, Hangzhou Normal University, Hangzhou, P.R. China
1 shared publication- Jing Yang
Zhejiang Key Laboratory of Medical Epigenetics, Department of Pathology and Pathophysiology, School of Basic Medical Sciences, Hangzhou Normal University, Hangzhou 311121, China
1 shared publication - Kefeng Sun1 shared publication
Latest Publications
- Open Access
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8675
Effects and Therapeutic Strategies of Intra-Hepatic Cellular Senescence and Regeneration
The liver constitutes a vital organ characterized by remarkable regenerative capacity, wherein intra-hepatic cellular senescence and regeneration exert pivotal regulatory functions in maintaining hepatic homeostasis and in developing therapeutic interventions for liver diseases. Intra-hepatic cellular aging is typically characterized by diminished proliferative capacity, genomic instability, mitochondrial dysfunction, and exacerbated inflammatory responses, all of which contribute to hepatic functional impairment and the pathogenesis of associated diseases. Liver regeneration depends upon the proliferation and differentiation of hepatocytes—processes stringently regulated by diverse signaling pathways and microenvironmental factors. Notably, the relationship between hepatocyte aging and regeneration embodies a fundamental paradox: whereas acute, transient senescence may facilitate tissue repair through the senescence-associated secretory phenotype (SASP), chronic accumulation of senescent cells disrupts the hepatic microenvironment and suppresses regenerative capacity. This duality necessitates nuanced therapeutic strategies capable of distinguishing between beneficial and detrimental senescent cell populations. Interventions targeting cellular senescence, encompassing small-molecule anti-aging compounds, gene therapy, and stem-cell-based approaches, may represent promising therapeutic modalities for future liver disease management. This review reviews the molecular mechanisms underlying hepatocyte aging and regeneration, critically examines the contradictory roles of senescence in hepatic repair, and explores strategies that selectively target pathological senescence to promote liver regeneration. These insights may provide novel perspectives for the prevention and treatment of liver diseases.
- 28 September 2026
- Published by MDPI AG in International Journal of Molecular Sciences
- Vol. 27 (19) , 8675
Open AccessEffects and Therapeutic Strategies of Intra-Hepatic Cellular Senescence and Regeneration
The liver constitutes a vital organ characterized by remarkable regenerative capacity, wherein intra-hepatic cellular senescence and regeneration exert pivotal regulatory functions in maintaining hepatic homeostasis and in developing therapeutic interventions for liver diseases. Intra-hepatic cellular aging is typically characterized by diminished proliferative capacity, genomic instability, mitochondrial dysfunction, and exacerbated inflammatory responses, all of which contribute to hepatic functional impairment and the pathogenesis of associated diseases. Liver regeneration depends upon the proliferation and differentiation of hepatocytes—processes stringently regulated by diverse signaling pathways and microenvironmental factors. Notably, the relationship between hepatocyte aging and regeneration embodies a fundamental paradox: whereas acute, transient senescence may facilitate tissue repair through the senescence-associated secretory phenotype (SASP), chronic accumulation of senescent cells disrupts the hepatic microenvironment and suppresses regenerative capacity. This duality necessitates nuanced therapeutic strategies capable of distinguishing between beneficial and detrimental senescent cell populations. Interventions targeting cellular senescence, encompassing small-molecule anti-aging compounds, gene therapy, and stem-cell-based approaches, may represent promising therapeutic modalities for future liver disease management. This review reviews the molecular mechanisms underlying hepatocyte aging and regeneration, critically examines the contradictory roles of senescence in hepatic repair, and explores strategies that selectively target pathological senescence to promote liver regeneration. These insights may provide novel perspectives for the prevention and treatment of liver diseases.
- 5 September 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 122
CAR-based immunotherapy for cardiac fibrosis: A new therapeutic frontier
- 5 September 2026
- Published by Elsevier in Ageing Research Reviews
- Vol. 122
CAR-based immunotherapy for cardiac fibrosis: A new therapeutic frontier
- Open Access
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Immediate Effect of Drug‐Eluting Balloon Angioplasty Combined With Cutting Balloon Predilatation for the Treatment of Coronary Artery Disease
Background: Cutting balloon (CB) can reduce vascular inflammation and elastic recoil, and these findings have been verified in combination with stent implantation in patients with coronary artery disease (CAD). This study aims to compare the immediate effect of CB with conventional balloon pre‐dilatation before drug‐eluting balloon (DEB) angioplasty for the treatment of CAD. Methods: Patients with CAD, diagnosed by elective coronary angiography and having either de novo lesions or in‐stent restenosis (ISR) were included. All patients were randomly assigned to undergo predilatation with either a CB or a conventional balloon prior to DEB treatment. We assessed the immediate effect and the level of inflammatory factors after the operation between two groups. Results: Eighty‐five patients were enrolled. In the CB group ( n = 42), all patients achieved residual stenosis < 30% (100% procedural success), with no acute complications observed. In the conventional balloon group ( n = 43), 6 patients had residual stenosis ≥ 30% (resulting in an 86.0% procedural success rate), and two acute complications occurred (one type B dissection and one acute branch occlusion), neither requiring bail‐out stenting. Moreover, serum levels of IL‐6, IL‐8, TNF‐α, and CRP at 24 h were significantly higher than those before and immediately after the operation in the two groups. The degrees of increase in concentration of IL‐6, IL‐8, and TNF‐α 24‐h postoperatively were lower in the CB group than those in the conventional balloon group ( P < 0.05). Conclusions: In the treatment of CAD with DEB angioplasty, predilatation with CB was associated with improved immediate procedural success and a reduced inflammatory response compared with conventional balloon predilatation.
- 1 January 2025
- Published by Wiley in Journal of Interventional Cardiology
- Vol. 2025 (1)
Open AccessImmediate Effect of Drug‐Eluting Balloon Angioplasty Combined With Cutting Balloon Predilatation for the Treatment of Coronary Artery Disease
Background: Cutting balloon (CB) can reduce vascular inflammation and elastic recoil, and these findings have been verified in combination with stent implantation in patients with coronary artery disease (CAD). This study aims to compare the immediate effect of CB with conventional balloon pre‐dilatation before drug‐eluting balloon (DEB) angioplasty for the treatment of CAD. Methods: Patients with CAD, diagnosed by elective coronary angiography and having either de novo lesions or in‐stent restenosis (ISR) were included. All patients were randomly assigned to undergo predilatation with either a CB or a conventional balloon prior to DEB treatment. We assessed the immediate effect and the level of inflammatory factors after the operation between two groups. Results: Eighty‐five patients were enrolled. In the CB group ( n = 42), all patients achieved residual stenosis < 30% (100% procedural success), with no acute complications observed. In the conventional balloon group ( n = 43), 6 patients had residual stenosis ≥ 30% (resulting in an 86.0% procedural success rate), and two acute complications occurred (one type B dissection and one acute branch occlusion), neither requiring bail‐out stenting. Moreover, serum levels of IL‐6, IL‐8, TNF‐α, and CRP at 24 h were significantly higher than those before and immediately after the operation in the two groups. The degrees of increase in concentration of IL‐6, IL‐8, and TNF‐α 24‐h postoperatively were lower in the CB group than those in the conventional balloon group ( P < 0.05). Conclusions: In the treatment of CAD with DEB angioplasty, predilatation with CB was associated with improved immediate procedural success and a reduced inflammatory response compared with conventional balloon predilatation.
- Open Access
- 20 July 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (7) , 1-14
DDX5-targeting fully human monoclonal autoantibody inhibits proliferation and promotes differentiation of acute promyelocytic leukemia cells by increasing ROS production
Acute promyelocytic leukemia (APL) therapy involves the compounds cytotoxic to both malignant tumor and normal cells. Relapsed APL is resistant to subsequent chemotherapy. Novel agents are in need to kill APL cells selectively with minimal toxicity. DDX5 has been recognized to be a novel target to suppress acute myeloid leukemia (AML). However, the role of DDX5 remains elusive in APL. Here a DDX5-targeting fully human monoclonal autoantibody named after 2F5 was prepared. It is demonstrated that 2F5 selectively inhibited APL cell proliferation without toxicity to normal neutrophil and tissues. Moreover, 2F5 was confirmed to induce G0/G1 phase arrest in APL cells, and promote APL cell differentiation combined with decreased DDX5 expression and increased reactive oxygen species (ROS) production. Knockdown of DDX5 by siRNA also inhibited proliferation, promoted cell differentiation and enhanced ROS production in APL cells. However, the ROS inhibitor reversed the effects of 2F5 on DDX5 and ROS in APL cells. Thus, we conclude that DDX5-targeting 2F5 inhibits APL cell proliferation, and promotes cell differentiation via induction of ROS. 2F5 showed the therapeutic value of fully human monoclonal autoantibody in APL, which provides a novel and valid approach for treatment of relapse/refractory APL.
- 20 July 2020
- Published by Springer Nature in Cell Death & Disease
- Vol. 11 (7) , 1-14
Open AccessDDX5-targeting fully human monoclonal autoantibody inhibits proliferation and promotes differentiation of acute promyelocytic leukemia cells by increasing ROS production
Acute promyelocytic leukemia (APL) therapy involves the compounds cytotoxic to both malignant tumor and normal cells. Relapsed APL is resistant to subsequent chemotherapy. Novel agents are in need to kill APL cells selectively with minimal toxicity. DDX5 has been recognized to be a novel target to suppress acute myeloid leukemia (AML). However, the role of DDX5 remains elusive in APL. Here a DDX5-targeting fully human monoclonal autoantibody named after 2F5 was prepared. It is demonstrated that 2F5 selectively inhibited APL cell proliferation without toxicity to normal neutrophil and tissues. Moreover, 2F5 was confirmed to induce G0/G1 phase arrest in APL cells, and promote APL cell differentiation combined with decreased DDX5 expression and increased reactive oxygen species (ROS) production. Knockdown of DDX5 by siRNA also inhibited proliferation, promoted cell differentiation and enhanced ROS production in APL cells. However, the ROS inhibitor reversed the effects of 2F5 on DDX5 and ROS in APL cells. Thus, we conclude that DDX5-targeting 2F5 inhibits APL cell proliferation, and promotes cell differentiation via induction of ROS. 2F5 showed the therapeutic value of fully human monoclonal autoantibody in APL, which provides a novel and valid approach for treatment of relapse/refractory APL.